Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
07 mars 2024 16h12 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
24 août 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
26 juil. 2022 07h00 HE
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...